1 |
Ain |
- |
- |
- |
- |
013 1件: 13 💬 |
2 |
Ain457 |
- |
- |
- |
- |
013 7件: 13, 37, 41, 46, 56, 96, 271 💬 |
3 |
Ain457, 150 mg |
- |
- |
- |
- |
271 1件: 271 💬 |
4 |
Ain457, 150mg |
- |
- |
- |
- |
037 1件: 37 💬 |
5 |
Ain457, 75 mg |
- |
- |
- |
- |
271 1件: 271 💬 |
6 |
Ain457a |
- |
- |
- |
- |
271 1件: 271 💬 |
7 |
Ain457f |
- |
- |
- |
- |
046 2件: 46, 271 💬 |
8 |
Humatrope 6 mg/12 mg/24 mg injektiokuiva-aine ja liuotin, liuosta varten |
- |
- |
- |
- |
193 1件: 193 💬 |
9 |
Remicade 100 mg infuusiokuiva-aine, konsentraattiliuosta varten |
- |
- |
- |
- |
097 1件: 97 💬 |
10 |
Secukinumab (ain457) |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
046 1件: 46 💬 |
11 |
Secukinumab (ain457) 150 mg s.c. |
Secukinumab |
1件: D09967 D09967 💬 |
IL17A 1件: IL17A 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation |
271 1件: 271 💬 |